License to Kill Tumors: How Much Hope is Justified for Trail

Authors: Frank, S.; Ebert, A.D.

Source: Current Drug Metabolism, Volume 7, Number 16, 1 November 2001 , pp. 1689-1701(13)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

In 1995, a new cytokine termed TRAIL (tumor necrosis factor - related apoptosis-inducing ligand) was discovered and demonstrated to selectively induce programmed cell death in transformed cell lines. Preclinical cytotoxicity studies in mice and nonhuman primates have produced promising results by demonstrating that TRAIL exerts potent tumoricidal activity but lacks severe toxicity towards normal tissues making it a potentially ideal candidate for cancer therapy. This article reviews aspects of our current understanding of TRAIL signaling pathways and summarizes how this knowledge is currently being translated into TRAIL-based tumor-selective therapeutic strategies

Keywords: Tumors; TRAIL (tumor necrosis factor; Tumor Necrosis Factor; Apoptosis; Fas-associated death domain; FADD converting enzyme; Interferon; Interleukin; C-Jun N-terminal kinase; Nuclear factor kappa B

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1381612013397212

Publication date: 2001-11-01

More about this publication?

Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.